{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:32:41Z","timestamp":1793035961125,"version":"4.5.0"},"reference-count":181,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["2R01AI118389"],"award-info":[{"award-number":["2R01AI118389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen\u2013host interactions, offer exciting and promising avenues for the development of new and improved vaccines.<\/jats:p>","DOI":"10.3390\/toxins15090563","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:57:17Z","timestamp":1694159837000},"page":"563","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines"],"prefix":"10.3390","volume":"15","author":[{"given":"Sonal","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8186-8810","authenticated-orcid":false,"given":"Sabine","family":"Pellett","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00262-016-1796-7","article-title":"Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity","volume":"65","author":"Bol","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"Volume 18","author":"Riedel","year":"2005","journal-title":"Baylor University Medical Center Proceedings"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow\u2019s vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/infdis\/168.1.29","article-title":"Vaccination in the 21st century","volume":"168","author":"Plotkin","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: Past, present and future","volume":"11","author":"Plotkin","year":"2005","journal-title":"Nat. Med."},{"key":"ref_8","first-page":"153","article-title":"Recombinant subunit vaccines: Potentials and constraints","volume":"121","author":"Clark","year":"2005","journal-title":"Dev. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.micpath.2015.05.004","article-title":"Evaluation of the combined use of the recombinant Brucella abortus Omp10, Omp19 and Omp28 proteins for the clinical diagnosis of bovine brucellosis","volume":"83\u201384","author":"Simborio","year":"2015","journal-title":"Microb. Pathog."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated Virus and Protein-Based COVID-19 Vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"703986","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques from Ebola, Sudan, and Marburg Viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/fmb-2021-0167","article-title":"Diphtheria-tetanus-pertussis vaccine: Past, current & future","volume":"17","author":"Prygiel","year":"2022","journal-title":"Future Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.bmb.a070689","article-title":"Diphtheria and tetanus toxoids","volume":"25","author":"Smith","year":"1969","journal-title":"Br. Med. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"01668-20","DOI":"10.1128\/mBio.01668-20","article-title":"A Novel High-Potency Tetanus Vaccine","volume":"11","author":"Przedpelski","year":"2020","journal-title":"mBio"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4049\/jimmunol.16.4.391","article-title":"The Effect of Formalin on Botulinum Toxins A, B and C","volume":"16","author":"Graham","year":"1929","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2500\/aap.2022.43.210105","article-title":"Delayed allergic skin reactions to vaccines","volume":"43","author":"Aquino","year":"2022","journal-title":"Allergy Asthma Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: Building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"ref_23","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). Vaccines, W.B. Saunders. [6th ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.inf.0000220209.35074.0b","article-title":"The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: A study of manufacturing consistency and persistence of antibody","volume":"25","author":"Lieberman","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00006454-200012000-00002","article-title":"Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up","volume":"19","author":"Patja","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0264-410X(98)00046-2","article-title":"Inactivated whole-cell bacterial vaccines: Current status and novel strategies","volume":"16","author":"Pace","year":"1998","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: Past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hird, T.R., and Grassly, N.C. (2012). Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002599"},{"key":"ref_29","unstructured":"World Health Organization (2023, July 01). Supplementary Information on Vaccine Safety. Part 2: Background Rates of Adverse Events Following Immunization. World Health Organization. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/66675."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/infdis\/jiac274","article-title":"Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants","volume":"226","author":"Ren","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_32","unstructured":"CDC (2023, July 01). Adverse Reaction, Available online: https:\/\/www.cdc.gov\/rabies\/specific_groups\/hcp\/adverse_reaction.html#:~:text=Immediate%20hypersensitivity%20reactions%20have%20been,6%2D14%20days%20after%20boosters."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-136-9-200205070-00008","article-title":"Serologic immunity to diphtheria and tetanus in the United States","volume":"136","author":"McQuillan","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.bioconjchem.7b00692","article-title":"Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles","volume":"29","author":"Angsantikul","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1128\/IAI.74.2.1001-1008.2006","article-title":"Stimulation of CD8 + T cells following diphtheria toxin-mediated antigen delivery into dendritic cells","volume":"74","author":"Shaw","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0974-777X.77298","article-title":"Combination vaccines","volume":"3","author":"Skibinski","year":"2011","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp.68.2.135","article-title":"Neurological aspects of tropical disease","volume":"68","author":"Farrar","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","first-page":"57","article-title":"Tetanus and Clostridium tetani\u2014A brief review","volume":"38","author":"Stock","year":"2015","journal-title":"Med. Monatsschr. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1542\/pir.2017-0238","article-title":"Tetanus Disease, Treatment, Management","volume":"39","author":"Rhinesmith","year":"2018","journal-title":"Pediatr. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02298124","article-title":"Enzymatic hydrolysis of tetanus toxin by intrinsic and extrinsic proteases. Characterization of the fragments by monoclonal antibodies","volume":"174","author":"Goretzki","year":"1985","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/jnnp.69.3.292","article-title":"Tetanus","volume":"69","author":"Farrar","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1016\/j.vaccine.2008.05.014","article-title":"Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production","volume":"26","author":"Kegel","year":"2008","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jchromb.2011.06.003","article-title":"Tetanus toxoid purification: Chromatographic procedures as an alternative to ammonium-sulphate precipitation","volume":"879","author":"Stojicevic","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rossetto, O., and Montecucco, C. (2019). Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins, 11.","DOI":"10.3390\/toxins11120686"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.vaccine.2006.12.033","article-title":"Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin","volume":"25","author":"Jorgensen","year":"2007","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11535","DOI":"10.1038\/s41598-020-68248-z","article-title":"Formaldehyde treatment of proteins enhances proteolytic degradation by the endo-lysosomal protease cathepsin S","volume":"10","author":"Michiels","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fan, Y.C., Chiu, H.C., Chen, L.K., Chang, G.J., and Chiou, S.S. (2015). Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Neglected Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004167"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.xphs.2019.10.047","article-title":"Identification of Formaldehyde-Induced Modifications in Diphtheria Toxin","volume":"109","author":"Metz","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1021\/acs.molpharmaceut.0c00851","article-title":"Novel Formaldehyde-Induced Modifications of Lysine Residue Pairs in Peptides and Proteins: Identification and Relevance to Vaccine Development","volume":"17","author":"Michiels","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJM195009212431204","article-title":"Immune responses and reactions to diphtheria and tetanus toxoids, with pertussis vaccine, aluminum phosphate precipitated","volume":"243","author":"Mc","year":"1950","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12640-019-00096-w","article-title":"Epitope Mapping of Tetanus Toxin by Monoclonal Antibodies: Implication for Immunotherapy and Vaccine Design","volume":"37","author":"Ghotloo","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ije\/dyq027","article-title":"Tetanus toxoid immunization to reduce mortality from neonatal tetanus","volume":"39","author":"Blencowe","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kyu, H.H., Mumford, J.E., Stanaway, J.D., Barber, R.M., Hancock, J.R., Vos, T., Murray, C.J., and Naghavi, M. (2017). Mortality from tetanus between 1990 and 2015: Findings from the global burden of disease study 2015. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4111-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-019-0131-y","article-title":"Diphtheria","volume":"5","author":"Sharma","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1111\/j.1742-4658.2006.05442.x","article-title":"A family of killer toxins. Exploring the mechanism of ADP-ribosylating toxins","volume":"273","author":"Holbourn","year":"2006","journal-title":"FEBS J."},{"key":"ref_57","unstructured":"World Health Organization (2023). WHO Site, World Health Organization."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: A table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/JB.01180-06","article-title":"Genetic diversity among Botulinum Neurotoxin-producing clostridial strains","volume":"189","author":"Hill","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tim.2004.08.002","article-title":"Presynaptic receptor arrays for clostridial neurotoxins","volume":"12","author":"Montecucco","year":"2004","journal-title":"Trends Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pbiomolbio.2015.02.004","article-title":"Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin","volume":"117","author":"Lam","year":"2015","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Whitemarsh, R.C., Tepp, W.H., Johnson, E.A., and Pellett, S. (2014). Persistence of botulinum neurotoxin a subtypes 1\u20135 in primary rat spinal cord cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090252"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"00089-18","DOI":"10.1128\/mBio.00089-18","article-title":"The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes","volume":"9","author":"Pellett","year":"2018","journal-title":"mBio"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gardner, A.P., and Barbieri, J.T. (2018). Light Chain Diversity among the Botulinum Neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10070268"},{"key":"ref_67","first-page":"55","article-title":"Botulism: The present status of the disease","volume":"195","author":"Hatheway","year":"1995","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1542\/pir.2015-0018","article-title":"Botulism","volume":"37","year":"2016","journal-title":"Pediatr. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sundeen, G., and Barbieri, J.T. (2017). Vaccines against Botulism. Toxins, 9.","DOI":"10.3390\/toxins9090268"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.mib.2012.05.009","article-title":"Vaccines against botulism","volume":"15","author":"Karalewitz","year":"2012","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_71","unstructured":"Centers for Disease Control and Prevention (2011). Notice of CDC\u2019s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb. Mortal. Wkly. Rep., 60, 1454\u20131455."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: Past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccin."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: Past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/IAI.00843-07","article-title":"Recombinant holotoxoid vaccine against botulism","volume":"76","author":"Pier","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/plas.1998.1366","article-title":"Conjugative transfer of the Escherichia coli-Clostridium perfringens shuttle vector pJIR1457 to Clostridium botulinum type A strains","volume":"40","author":"Bradshaw","year":"1998","journal-title":"Plasmid"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.micro.53.1.551","article-title":"Clostridial toxins as therapeutic agents: Benefits of nature\u2019s most toxic proteins","volume":"53","author":"Johnson","year":"1999","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum neurotoxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7883\/yoken.JJID.2016.360","article-title":"Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan","volume":"70","author":"Torii","year":"2017","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.4049\/jimmunol.174.4.2190","article-title":"A novel neurotoxoid vaccine prevents mucosal botulism","volume":"174","author":"Kobayashi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/S0264-410X(02)00157-3","article-title":"Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid","volume":"20","author":"Torii","year":"2002","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/plas.1997.1329","article-title":"Genetically engineered vaccines: An overview","volume":"39","author":"Dertzbaugh","year":"1998","journal-title":"Plasmid"},{"key":"ref_83","first-page":"396","article-title":"A New Approach to Bacterial Vaccines","volume":"89","author":"Greenberg","year":"1963","journal-title":"Can. Med. Assoc. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsps.2011.06.003","article-title":"Vaccine adjuvants\u2014Current status and prospects on controlled release adjuvancity","volume":"19","author":"Sivakumar","year":"2011","journal-title":"Saudi. Pharm. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4615-1823-5_8","article-title":"Adjuvant properties of aluminum and calcium compounds","volume":"6","author":"Gupta","year":"1995","journal-title":"Pharm. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Diaz-Dinamarca, D.A., Salazar, M.L., Castillo, B.N., Manubens, A., Vasquez, A.E., Salazar, F., and Becker, M.I. (2022). Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081671"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2014.03.078","article-title":"How advances in immunology provide insight into improving vaccine efficacy","volume":"32","author":"Slifka","year":"2014","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: Putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/21645515.2020.1732166","article-title":"Hepatitis B vaccine development and implementation","volume":"16","author":"Zhao","year":"2020","journal-title":"Hum. Vaccine Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00063030-199810020-00005","article-title":"Recombinant hepatitis B vaccine: A review of its immunogenicity and protective efficacy against hepatitis B","volume":"10","author":"Adkins","year":"1998","journal-title":"BioDrugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/TCRM.S856","article-title":"A novel vaccine for cervical cancer: Quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil)","volume":"4","author":"Govan","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/aem.46.3.560-564.1983","article-title":"Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197","volume":"46","author":"Rappuoli","year":"1983","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.toxicon.2007.09.010","article-title":"Diphtheria toxin mutant CRM197 is an inhibitor of protein synthesis that induces cellular toxicity","volume":"51","author":"Qiao","year":"2008","journal-title":"Toxicon"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jb\/mvm116","article-title":"Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity","volume":"142","author":"Kageyama","year":"2007","journal-title":"J. Biochem."},{"key":"ref_99","unstructured":"Rabadi, T., and Brady, M.F. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_100","unstructured":"World Health Organization (2013). Vaccine Safety Basics, World Health Organization."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.toxicon.2020.08.001","article-title":"Evaluation of a recombinant tetanus toxin subunit vaccine","volume":"187","author":"Liu","year":"2020","journal-title":"Toxicon"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1016\/j.vaccine.2022.07.011","article-title":"Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein","volume":"40","author":"Chang","year":"2022","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil, C., and Popoff, M.R. (2019). Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches. Toxins, 11.","DOI":"10.3390\/toxins11090528"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0041-0101(95)00072-T","article-title":"Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen","volume":"33","author":"LaPenotiere","year":"1995","journal-title":"Toxicon"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/IAI.00382-13","article-title":"Enhancing the protective immune response against botulism","volume":"81","author":"Przedpelski","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.vaccine.2018.02.042","article-title":"Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A\/B, in volunteers with pre-existing botulinum toxoid immunity","volume":"36","author":"Khouri","year":"2018","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Webb, R.P., Smith, T.J., Smith, L.A., Wright, P.M., Guernieri, R.L., Brown, J.L., and Skerry, J.C. (2017). Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins, 9.","DOI":"10.3390\/toxins9090269"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pep.2009.12.013","article-title":"Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery","volume":"71","author":"Band","year":"2010","journal-title":"Protein Expr. Purif."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Tepp, W.H., Bradshaw, M., Gardner, A.P., Kaufman, R.L., Barbieri, J.T., and Pellett, S. (2023). Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065690"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/AEM.01795-14","article-title":"Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System","volume":"80","author":"Bradshaw","year":"2014","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/j.1742-4658.2011.08205.x","article-title":"Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators","volume":"278","author":"Dolly","year":"2011","journal-title":"FEBS J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1111\/j.1742-4658.2011.08196.x","article-title":"Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin","volume":"278","author":"Rummel","year":"2011","journal-title":"FEBS J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","article-title":"Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3","volume":"27","author":"Webb","year":"2009","journal-title":"Vaccine"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Webb, R.P. (2018). Engineering of Botulinum Neurotoxins for Biomedical Applications. Toxins, 10.","DOI":"10.3390\/toxins10060231"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1128\/IAI.73.9.5450-5457.2005","article-title":"Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization","volume":"73","author":"Smith","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","article-title":"Enhancing toxin-based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Vaccine"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Li, Z., Lu, J., Tan, X., Wang, R., Xu, Q., Yu, Y., and Yang, Z. (2022). Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E. Toxins, 14.","DOI":"10.3390\/toxins14020135"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Li, Z., Li, B., Lu, J., Liu, X., Tan, X., Wang, R., Du, P., Yu, S., Xu, Q., and Pang, X. (2023). Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F. Toxins, 15.","DOI":"10.3390\/toxins15030200"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15776","DOI":"10.1038\/srep15776","article-title":"Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin","volume":"5","author":"Ayyar","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/B:JOPC.0000016257.91979.06","article-title":"Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A","volume":"23","author":"Atassi","year":"2004","journal-title":"Protein J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxicon.2015.06.003","article-title":"Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions","volume":"107 Pt A","author":"Atassi","year":"2015","journal-title":"Toxicon"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/IAI.01252-08","article-title":"Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes","volume":"77","author":"Shone","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/bi0157969","article-title":"Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization","volume":"41","author":"Binz","year":"2002","journal-title":"Biochemistry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8291","DOI":"10.1021\/bi050253a","article-title":"Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme","volume":"44","author":"Agarwal","year":"2005","journal-title":"Biochemistry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-015-1816-x","article-title":"In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A","volume":"33","author":"Ravichandran","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum neurotoxin is shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 5, 536\u2013544.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"ref_132","first-page":"1","article-title":"Coronavirus genome structure and replication","volume":"287","author":"Brian","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2021). COVID-19: Characteristics and Therapeutics. Cells, 10.","DOI":"10.3390\/cells10020206"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1002\/rmv.2313","article-title":"COVID-19 vaccines and variants of concern: A review","volume":"32","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"714170","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13337-020-00571-5","article-title":"Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)","volume":"31","author":"Kumar","year":"2020","journal-title":"Virusdisease"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2013.10.013","article-title":"Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS","volume":"101","author":"Drexler","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"eabq6978","DOI":"10.1126\/sciadv.abq6978","article-title":"The repertoire of CSF antiviral antibodies in patients with neuroinflammatory diseases","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"111022","DOI":"10.1016\/j.celrep.2022.111022","article-title":"COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins","volume":"40","author":"Elko","year":"2022","journal-title":"Cell Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.scr.2020.102125","article-title":"Neutralizing antibodies targeting SARS-CoV-2 spike protein","volume":"50","author":"Xiaojie","year":"2020","journal-title":"Stem Cell Res."},{"key":"ref_146","unstructured":"Novavax (2023, July 01). Novavax\u2019s Nuvaxovid\u2122 Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU. Available online: https:\/\/ir.novavax.com\/press-releases\/2023-05-26-Novavaxs-Nuvaxovid-TM-Receives-Positive-CHMP-Opinion-for-Full-Marketing-Authorization-for-the-Prevention-of-COVID-in-the-EU."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current Developments and Challenges of mRNA Vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/08971900211009650","article-title":"Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273","volume":"35","author":"Teo","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death during the Delta-Predominant Period","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.033","article-title":"Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care","volume":"159","author":"Garreffa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/ajt.16517","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine\u2014United States, 21 December 2020\u201310 January 2021","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am. J. Transpl."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team, and Food and Drug Administration (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine\u2014United States, 21 December 2020\u201310 January 2021. MMWR Morb. Mortal. Wkly. Rep., 70, 125\u2013129.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamapediatrics.2022.6166","article-title":"Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada","volume":"177","author":"Buchan","year":"2023","journal-title":"JAMA Pediatr."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Singer, M.E., Taub, I.B., and Kaelber, D.C. (2022). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv, medRxiv:2021.07.23.21260998.","DOI":"10.1101\/2021.07.23.21260998"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"Custers","year":"2021","journal-title":"Vaccine"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Koger-Pease, C., Perera, D.J., and Ndao, M. (2023). Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030334"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/postgradmedj-2021-140654","article-title":"Review of COVID-19 vaccine subtypes, efficacy and geographical distributions","volume":"98","author":"Francis","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"ref_166","unstructured":"Food and Drug Administration (USFDA) (2023, July 01). Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCULATIONAHA.123.063396","article-title":"Shedding Light on Mechanisms of Myocarditis with COVID-19 mRNA Vaccines","volume":"147","author":"Bozkurt","year":"2023","journal-title":"Circulation"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Hajjo, R., Sabbah, D.A., Bardaweel, S.K., and Tropsha, A. (2021). Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines, 9.","DOI":"10.3390\/vaccines9101186"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"11664","DOI":"10.1038\/s41598-022-15876-2","article-title":"Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes","volume":"12","author":"Mukherjee","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Tomic, M.T., Farr-Jones, S., Syar, E.S., Niemuth, N., Kobs, D., Hackett, M.J., Espinoza, Y., Martinez, Z., Pham, K., and Snow, D.M. (2021). Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Toxins, 13.","DOI":"10.3390\/toxins13090671"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1656(99)00107-8","article-title":"Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines","volume":"73","author":"Liljeqvist","year":"1999","journal-title":"J. Biotechnol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"119843","DOI":"10.1016\/j.ijpharm.2020.119843","article-title":"Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability","volume":"589","author":"Mabrouk","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Xu, S., Yang, K., Li, R., and Zhang, L. (2020). mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186582"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Hotez, P.J., and Bottazzi, M.E. (2020). Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Neglected Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008548"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the Cold Reality of mRNA Vaccine Stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/563\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:18Z","timestamp":1760129238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":181,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["toxins15090563"],"URL":"https:\/\/doi.org\/10.3390\/toxins15090563","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}